Year: 2025 | Month: February | Volume: 15 | Issue: 2 | Pages: 241-255
DOI: https://doi.org/10.52403/ijhsr.20250232
Pathophysiology and Clinical Perception of Immune Dysregulation in Chronic Liver Disease Accelerated by Acute Kidney Injury
P. Kishore Kumar1, Bagadam Aparna1, K. Mallikarjun Rao1, Syed Mohiuddin Quadri1, Tadikonda Rama Rao2
1Associate Professor, CMR college of Pharmacy, Kandlakoya-501401, Hyderabad, Telangana.
1Student, CMR college of Pharmacy, Kandlakoya-501401, Hyderabad, Telangana.
2Principal & Professor, CMR college of Pharmacy, Kandlakoya-501401, Hyderabad, Telangana.
Corresponding Author: Dr. P. Kishore Kumar
ABSTRACT
Abstraction Immune dysfunction, in particular cirrhosis-associated immune dysfunction (CAID), has been associated to chronic liver disease (CLD), a global health concern the fact that places patients vulnerable for infections and systemic inflammation. Because of variables like hepatorenal syndrome, sepsis, and hypovolemia, acute kidney injury (AKI) commonly exacerbates immune-mediated dysregulation and complicates chronic renal failure (CLD). This review examines the complicated relationship between immune system dysfunction and AKI in CLD. T-cell exhaustion and impaired B-cell activity influence adaptive immunity in CLD, while faulty neutrophils, monocytes, and natural killer cells describe poor innate immunity. By generating damage-associated molecular patterns (DAMPs) and advancing cytokine storms, AKI aggravates these processes, leading to immune-mediated paralysis and systemic inflammation. This review highlights the critical need for mechanistic studies, early diagnostic tools, and customised therapeutic approaches to mitigate the profound impact of AKI on immune dysfunction in CLD and improve patient outcomes. The combined consequences of CLD and AKI enhance the likelihood of serious illnesses, like spontaneous bacterial peritonitis and sepsis, and contribute to adverse clinical outcomes, including greater mortality and prolonged being hospitalised. Rising biomarkers and therapies, such as probiotics and anti-inflammatory agents, offer promising avenues for managing immune dysfunction in AKI-CLD interplay.
Key words: DAMP, Immune dysfunction, adaptive immunity, Innate immunity